Mithra Pharmaceuticals SA (MITRA.BR)

0,2160 0,0000 (0,00%) Börsenschluss: 05:35PM CEST

Mithra Pharmaceuticals SA

Rue Saint-Georges 5
Liège 4000
Belgium
32 4 349 28 22
https://www.mithra.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christophe Marechal	Co-CEO & CFO	N/A	N/A	N/A
Mr. Xavier Paoli M.Sc.	COO & Co-CEO	N/A	N/A	N/A
Dr. Graham K. Dixon Ph.D.	Chief Scientific Officer	N/A	N/A	1961
Mr. Alex Sokolowski	Head of Investor Relations	N/A	N/A	N/A
Fanny Rozenberg	Secretary of the Board & General Counsel	N/A	N/A	N/A
Fanny Storms	Compliance Officer	N/A	N/A	N/A
Mr. Frederique Depraetere	Communication Director	N/A	N/A	N/A
Ms. Catherine Lejeune	HR Director	N/A	N/A	N/A
Mr. Jean-Manuel Fontaine	Chief Commercial & External Affairs Officer	N/A	N/A	N/A
Prof. Jean-Michel Foidart M.D., Ph.D.	President of the Scientific Advisory Board & Executive Director	7,12k	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2016 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Corporate Governance

Mithra Pharmaceuticals SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.